Stock Taper 
Cellectis S.A. is a Paris-based biotech company developing gene-edited CAR T-cell immunotherapies for various cancers, with strategic partnerships and multiple clinical-stage product candidates targeting hematologic malignancies and solid tumors.
Lasme-cel is an off-the-shelf CAR T-cell therapy targeting CD22 for relapsed/refractory B-cell ALL, advancing toward Phase 2 trials as a key innovative, non-patient-specific cancer treatment by Cellectis.
Cellectis hosted an R&D Day in New York City, presenting the complete Phase 1 dataset for its lead product candidate, lasme-cel (UCART22), in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The data highlighted a 68% overall response rate, which increased to 83% at the recommended Phase 2 dose and 100% in the target patient population, leading to a significant positive market reaction. [18, 22]
In a transformational move for the company, Cellectis initiated the pivotal Phase 2 BALLI-01 clinical trial for its lead allogeneic CAR T-cell therapy candidate, lasme-cel. This decision transitions the company from an early-stage to a late-stage clinical development entity, focusing its resources on the final steps before potential regulatory approval for patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL).
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis NASDAQ: CLLS outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through one-time intravenous treatments.
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 DRTS | $13.77 | COMPARE |
 ANRO | $23.80 | COMPARE |
 SLN | $9.27 | COMPARE |
 LRMR | $2.68 | COMPARE |
 ACIU | $2.57 | COMPARE |
 AMRN | $11.99 | COMPARE |
 DBVT | $9.53 | COMPARE |
 KRRO | $10.53 | COMPARE |
